Published in Rev Recent Clin Trials on September 01, 2009
Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob Agents Chemother (2013) 0.86
Identification of ligands that target the HCV-E2 binding site on CD81. J Comput Aided Mol Des (2013) 0.75
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA (2004) 1.78
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol (2002) 1.42
Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun (2009) 1.41
MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut (2012) 1.40
Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun (2011) 1.39
Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. Lab Invest (2004) 1.38
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut (2006) 1.31
Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology (2006) 1.31
BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol (2005) 1.28
Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology (2003) 1.24
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Macrophage scavenger receptor down-regulates mycobacterial cord factor-induced proinflammatory cytokine production by alveolar and hepatic macrophages. Microb Pathog (2006) 1.20
Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-β-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol (2011) 1.19
Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res (2007) 1.13
Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem (2003) 1.13
Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res (2003) 1.11
Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? J Gastroenterol (2013) 1.08
Identification of vitamin A-free cells in a stellate cell-enriched fraction of normal rat liver as myofibroblasts. Histochem Cell Biol (2006) 1.08
Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology (2003) 1.08
Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology (2005) 1.06
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol (2012) 1.04
Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology (2005) 1.04
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol (2011) 1.02
Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair (2012) 1.02
Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb (2009) 1.02
Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice. Am J Pathol (2011) 1.02
Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. Gastroenterology (2002) 1.01
Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol (2010) 1.00
Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci (2014) 0.99
Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Lab Invest (2009) 0.99
Structural characterization of the proximal and distal histidine environment of cytoglobin and neuroglobin. Biochemistry (2005) 0.99
Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol (2005) 0.98
Characterization of the heme environmental structure of cytoglobin, a fourth globin in humans. Biochemistry (2003) 0.98
Asymptomatic chronic intestinal ischemia caused by idiopathic phlebosclerosis of mesenteric vein. Dig Dis Sci (2002) 0.97
Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World J Gastroenterol (2006) 0.97
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol (2011) 0.97
p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection. Intervirology (2004) 0.97
Structural basis of human cytoglobin for ligand binding. J Mol Biol (2004) 0.96
Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology (2013) 0.96
Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas (2009) 0.96
Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res (2010) 0.95
Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol (2009) 0.94
The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer (2013) 0.94
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol (2011) 0.94
Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res (2006) 0.94
Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab (2006) 0.94
Typing of hepatic nonparenchymal cells using fibulin-2 and cytoglobin/STAP as liver fibrogenesis-related markers. Histochem Cell Biol (2004) 0.94
Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol (2008) 0.94
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther (2007) 0.93
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas (2010) 0.93
Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res (2003) 0.93
Hepatic sinusoidal cells in health and disease: update from the 14th International Symposium. Liver Int (2009) 0.93
A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol (2010) 0.92
HLA class II associated with outcomes of hepatitis B and C infections. World J Gastroenterol (2013) 0.92
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol (2007) 0.92
Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet (2004) 0.92
Characterization of human stellate cell activation-associated protein and its expression in human liver. Biochim Biophys Acta (2002) 0.92
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol (2011) 0.91
Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med (2008) 0.91
Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol (2009) 0.90
Cytoglobin, a novel member of the globin family, protects kidney fibroblasts against oxidative stress under ischemic conditions. Am J Pathol (2010) 0.90
Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol (2013) 0.90
Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res (2010) 0.90
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther (2014) 0.89
Successful treatment of giant rectal varices by modified percutaneous transhepatic obliteration with sclerosant: Report of a case. World J Gastroenterol (2006) 0.89
Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. Oncology (2013) 0.89
Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res (2013) 0.88
Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J Med Virol (2005) 0.88
Regulation of cultured rat hepatocyte proliferation by stellate cells. J Hepatol (2002) 0.88
Fascin, a novel marker of human hepatic stellate cells, may regulate their proliferation, migration, and collagen gene expression through the FAK-PI3K-Akt pathway. Lab Invest (2011) 0.87
Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis. Virchows Arch (2002) 0.87
Rho kinases regulate endothelial invasion and migration during valvuloseptal endocardial cushion tissue formation. Dev Dyn (2006) 0.87
Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One (2013) 0.86
Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. Hepatol Res (2011) 0.86
Involvement of Galectin-1 and Galectin-3 in Proliferation and Migration of Rat Hepatic Stellate Cells in Culture. Comp Hepatol (2004) 0.85
Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res (2003) 0.85
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther (2014) 0.85
Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatol Res (2012) 0.85
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol (2005) 0.84